JUL 21 2026
Outlook Therapeutics — LYTENAVA (bevacizumab-vikg) $OTLK
for neovascular (wet) age-related macular degeneration
About
LYTENAVA is a bevacizumab antibody designed for direct injection into the eye to block the VEGF-A protein that drives abnormal blood vessel growth. In wet age-related macular degeneration, this unchecked growth causes fluid leaks and rapid central vision loss. By delivering the proven VEGF-blocking mechanism in a formulation specifically approved for the eye, LYTENAVA could provide a standardized treatment option for this serious condition.
Drug Watch — recent news on LYTENAVA
- Outlook: 'Hold' - Caution On LYTENAVA FDA Approval And Cash Needs (NASDAQ:OTLK) - Seeking Alpha
- Outlook Therapeutics wins FDA nod for Lytenava in neovascular AMD - indianpharmapost.com
- Outlook Therapeutics Wins FDA Approval For Lytenava After Four Attempts To Bring Bevacizumab Eye Drug To Market - londoninsider.co.uk
- Outlook Therapeutics wins FDA approval for Lytenava in wet AMD - finance.yahoo.com
- FDA Approves Outlook Therapeutics’ Lytenava to Treat Wet AMD - VisionMonday.com
Sponsor Watch — recent news on Outlook Therapeutics
- Outlook Therapeutics wins FDA approval for Lytenava in wet AMD
- Outlook Therapeutics shares climb after FDA clears LYTENAVA for wet AMD
- Outlook Therapeutics Announces LYTENAVA™ FDA Approval as the First and Only FDA-Approved Ophthalmic Bevacizumab for the Treatment of Wet AMD
- Outlook Therapeutics (OTLK) Gets July 29 PDUFA Date for LYTENAVA
- OTLK Stock Soars 28% After FDA Sets July Date For Lytenava Decision